6. Product Development Priorities
|
Table 6.2: Selected Initiatives of the TDR
Selected Initiatives of the TDR| Disease | Product | Partner | Status | | Uncomplicated malaria | Lapdap | GlaxoSmithKline | Dossier submitted (2002) | | Lapdap, artesunate | GlaxoSmithKline | Phase 1 | | Pyronaridine, artesunate | Shin Poong | Preclinical trials | | Severe malaria | Intramuscular artemether | Artecef | Registered (2000) | | Rectal artesunate | Under discussion | FDA approval letter received | | Visceral leishmaniasis | Miltefosine | Zentaris | Registered (2002) | | Paromomycin | Institute for One World Health | Phase 3 studies | | Sleeping sickness | Intravenous eflornithine | Aventis | Registered (2001) | | River blindness | Ivermectin | Merck | Registered (1989) | |
|
|
© 2006 The World Bank Group, All Rights Reserved.
|
